Search

Your search keyword '"Carroll, W.M."' showing total 250 results

Search Constraints

Start Over You searched for: Author "Carroll, W.M." Remove constraint Author: "Carroll, W.M."
250 results on '"Carroll, W.M."'

Search Results

2. Changes in serum neurofilament light chain levels following narrowband ultraviolet B phototherapy in clinically isolated syndrome

Catalog

Books, media, physical & digital resources

3. Longitudinally extensive myelopathy in Caucasians: a West Australian study of 26 cases from the Perth Demyelinating Diseases Database

5. NMOSD and MS prevalence in the Indigenous populations of Australia and New Zealand

6. Narrowband UVB phototherapy alters peripheral blood immune cell frequencies in people with clinically isolated syndrome

10. Short-term changes in frequencies of circulating leukocytes associated with narrowband UVB phototherapy in people with clinically isolated syndrome

12. The origin of remyelinating oligodendrocytes in antiserum-mediated demyelinative optic neuropathy

13. Serum Anti-JCV antibody status in Western Australian patients with multiple sclerosis

14. Efficacy and safety of mitoxantrone use in aggressive Multiple Sclerosis (P3.414)

15. Prevalence of anti-aquaporin 4 antibody in a diagnostic cohort of patients being investigated for possible neuromyelitis optica spectrum disorder in Western Australia

16. Higher serum immunoglobulin G3 levels may predict the development of multiple sclerosis in individuals with Clinically Isolated Syndrome

17. Tryptophan and arginine catabolic enzymes and regulatory cytokines in clinically isolated syndrome and multiple sclerosis

18. A randomised, controlled clinical trial of narrowband UVB phototherapy for clinically isolated syndrome: The PhoCIS study

19. Narrowband UVB Phototherapy for Clinically Isolated Syndrome: Delivering the Benefits of All UVB-Induced Molecules

20. Low Prevalence of Anti Aquaporin 4 Antibody in Neuromyelitis Optica Spectrum Disorder and Multiple Sclerosis in Western Australia

21. Natural history of benign multiple sclerosis: Clinical and HLA correlates in a Western Australian cohort

22. Incidence and prevalence of NMOSD in Australia and New Zealand

23. Altered regulatory T-cell fractions and Helios expression in clinically isolated syndrome: Clues to the development of multiple sclerosis

24. Lymphocyte reconstitution following autologous stem cell transplantation for progressive MS

25. Narrowband UVB phototherapy for clinically isolated syndrome: A trial to deliver the benefits of Vitamin D and other UVB-Induced molecules

26. Circulating immune cells in multiple sclerosis

27. Asymptomatic progressive multifocal leukoencephalopathy during natalizumab therapy with treatment

28. Identifying Patient-Specific Epstein-Barr nuclear antigen-1 genetic variation and potential autoreactive targets relevant to multiple sclerosis pathogenesis

29. A new era in the treatment of multiple sclerosis

30. Helicobacter pylori infection as a protective factor against multiple sclerosis risk in females

31. Autologous stem cell transplantation in multiple sclerosis: Results from a single centre

32. Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: An Australian and New Zealand perspective Part 2 New and emerging therapies and their efficacy

33. Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: An Australian and New Zealand perspective Part 3 Treatment practicalities and recommendations

34. Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: An Australian and New Zealand perspective Part 1 Historical and established therapies

35. Resequencing and fine-mapping of the chromosome 12q13-14 locus associated with multiple sclerosis refines the number of implicated genes

36. The influence of non-HLA gene polymorphisms and interactions on disease risk in a Western Australian multiple sclerosis cohort

37. Benign multiple sclerosis: A longitudinal follow-up study of large Western Australian cohort

38. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis

39. Hypothalamic lesions in multiple sclerosis

40. HLA-DR allele polymorphism and multiple sclerosis in Chinese populations: a meta-analysis

41. Spinal cord involvement in multiple sclerosis: A correlative MRI and high-resolution HLA-DRB1 genotyping study

42. Wedge-shaped medullary lesions in multiple sclerosis

43. HLA-DRB1 allele heterogeneity influences multiple sclerosis severity as well as risk in Western Australia

44. Modifying effects of HLA-DRB1 allele interactions on age at onset of multiple sclerosis in Western Australia

45. Low level of systemic autoimmunity in Western Australian multiple sclerosis patients

46. Influence of HLA-DRB1 allele heterogeneity on disease risk and clinical course in a West Australian MS cohort: a high-resolution genotyping study

47. Clinical profile and HLA-DRB1 genotype of late onset multiple sclerosis in Western Australia

48. Presence of CSF oligoclonal bands (OCB) is associated with the HLA-DRB1 genotype in a West Australian multiple sclerosis cohort

49. Genome-wide association study identifies new multiple sclerosis susceptibility loci on chromosomes 12 and 20

50. Wallenberg syndrome caused by multiple sclerosis mimicking stroke